Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Phase 3
Terminated
- Conditions
- Head and Neck Neoplasms
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3
- Registration Number
- NCT02183246
Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02183662
Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Telmisartan/AmlodipineDrug: Telmisartan/Amlodipine/HCTZDrug: Telmisartan/HCTZ
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02183675
- Locations
- 🇯🇵
1348.5.001 Boehringer Ingelheim Investigational Site, Kanagawa , Yokohama, Japan
Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02182713
Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin/pioglitazone, FDC formulation C8Drug: Linagliptin/pioglitazone, FDC formulation C5
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT02183636
Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: GINSANA
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 29
- Registration Number
- NCT02182882
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: BIBF 1120 low doseDrug: BIBF 1120 high dose
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 81
- Registration Number
- NCT02182063
Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects
Phase 4
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 82
- Registration Number
- NCT02183155
Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Meloxicam, low doseDrug: Meloxicam, medium doseDrug: Meloxicam, high dose
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181309
Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 684
- Registration Number
- NCT02181335